Clinical Trials Logo
  1. Home
  2. Antibiotic Resistant Infection
  3. NCT06028217

Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment — CHAPTER  

Antibiotic Resistant Infection Clinical Trial

Official title:
A Prospective Study on Pathogen Investigation, Risk Factors, and Prognostic Factors Analysis of Hospital Acquired Pneumonia (HAP)

Clinical Trial Summary

The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China. The main purposes of this study are: 1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China; 2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06028217
Study type Observational
Source Ruijin Hospital
Contact
Status Not yet recruiting
Phase
Start date October 1, 2023
Completion date December 31, 2027
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05502380 - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Phase 3
Withdrawn NCT04462133 - Optimal Tailored Treatment for H. Pylori Infection N/A
Completed NCT03535324 - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT) N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Active, not recruiting NCT03865706 - Inulin for Infections in the Intensive Care Unit Phase 2
Completed NCT05391035 - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting NCT05224401 - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs Phase 3
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated NCT03535272 - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Phase 3
Recruiting NCT05902299 - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting NCT05293483 - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting NCT05561504 - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting NCT03606031 - Digestive Microbiota Transplant
Completed NCT01573195 - Merck IISP Stewardship Grant for Antibiotic Best Practices Phase 4
Not yet recruiting NCT03857295 - Infections Following NeuroSurgery (INS)
Not yet recruiting NCT03180983 - Antibiotic Use in French Nursing Home N/A